Spanopoulos, D., Barrett, B., Busse, M., Roman, T
Semaglutide works via GLP-1 receptor activation, stimulating glucose-dependent insulin release and slowing gastric emptying
Watching for serious side effects, like thyroid tumors or gallbladder trouble, is needed
It can be taken with or without food, providing flexibility for the patient's dietary needs and preferences
--- [5] McCarty MF
The GLP-1 receptor agonists segment dominated the market with a share of 86% in 2025, as GLP-1 receptor agonists are driving historic market expansion by transforming obesity and diabetes management into a billion-dollar global industry